AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10574355 — intervention group
Group type: EXPERIMENTAL
Intervention: Shifts of a textured background in the same direction as the target during smooth pursuit initiation
Number of subjects: 0
Study 10574355 — intervention group
Group type: COMPARATOR
Intervention: Shifts of a textured background opposite to the target direction
Number of subjects: 0
Study 8576779 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 0
Study 8576779 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor modification (cholesterol reduction therapy)
Number of subjects: 0
Study 8576779 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure reduction
Number of subjects: 0
Study 8576779 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists and diuretics
Number of subjects: 0
Study 2614768 — intervention group
Group type: EXPERIMENTAL
Intervention: Restore
Number of subjects: 4
Study 2614768 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfeel Ulcus
Number of subjects: 4
Study 2614768 — intervention group
Group type: COMPARATOR
Intervention: DuoDERM
Number of subjects: 4
Study 884003 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate
Number of subjects: 48
Study 884003 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate plus beta-pyridylcarbinol
Number of subjects: 48
Study 884003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 31174224 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocuff-assisted colonoscopy
Number of subjects: 122
Study 31174224 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 122
Study 28806348 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 100 mg/day
Number of subjects: 82
Study 28806348 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 200 mg/day
Number of subjects: 82
Study 28806348 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 300 mg/day
Number of subjects: 82
Study 28806348 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin E)
Number of subjects: 82
Study 28806348 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison among groups
Number of subjects: 82
Study 25698164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) for PTSD
Number of subjects: 50
Study 23228158 — intervention group
Group type: EXPERIMENTAL
Intervention: BPDSI-IV interview
Number of subjects: 71
Study 21521539 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate (LC) diet (4 % carbohydrate)
Number of subjects: 16
Study 21521539 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Carbohydrate (MC) diet (35 % carbohydrate)
Number of subjects: 16
Study 21521539 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate (LC) diet
Number of subjects: 16
Study 21521539 — intervention group
Group type: COMPARATOR
Intervention: Low Carbohydrate (LC) diet and Moderate Carbohydrate (MC) diet
Number of subjects: 16
Study 19080128 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with cisplatin and fluorouracil (PF) regimen
Number of subjects: 8
Study 19080128 — intervention group
Group type: COMPARATOR
Intervention: Control group (locoregional treatment alone)
Number of subjects: 8
Study 16966497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 16966497 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zolmitriptan nasal spray (ZNS5)
Number of subjects: 92
Study 16966497 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zolmitriptan nasal spray (ZNS10)
Number of subjects: 92
Study 16966497 — intervention group
Group type: COMPARATOR
Intervention: Placebo (episodic cluster headache)
Number of subjects: 92
Study 16966497 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zolmitriptan nasal spray (ZNS5) (episodic cluster headache)
Number of subjects: 92
Study 16966497 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zolmitriptan nasal spray (ZNS10) (episodic cluster headache)
Number of subjects: 92
Study 16966497 — intervention group
Group type: COMPARATOR
Intervention: Placebo (chronic cluster headache)
Number of subjects: 92
Study 16966497 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zolmitriptan nasal spray (ZNS5) (chronic cluster headache)
Number of subjects: 92
Study 16966497 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zolmitriptan nasal spray (ZNS10) (chronic cluster headache)
Number of subjects: 92
Study 12772019 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise program (individualized exercise program performed three times a week)
Number of subjects: 18
Study 12772019 — intervention group
Group type: COMPARATOR
Intervention: Usual exercise routine (control group)
Number of subjects: 18
Study 10852272 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5 (Marcaine)
Number of subjects: 34
Study 10852272 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (Control)
Number of subjects: 34
Study 10852272 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 34
Study 9199607 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation tube insertion
Number of subjects: 40
Study 9199607 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure equalization
Number of subjects: 40
Study 9199607 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure variation
Number of subjects: 40
Study 9199607 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine implantation of tympanic ventilation tubes
Number of subjects: 40
Study 1287425 — intervention group
Group type: EXPERIMENTAL
Intervention: Tannin albuminate/ethacridine lactate (TA/EL)
Number of subjects: 186
Study 1287425 — intervention group
Group type: COMPARATOR
Intervention: Charcoal
Number of subjects: 186
Study 3159401 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuramide therapy
Number of subjects: 20
Study 30166322 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban Training
Number of subjects: 407
Study 30166322 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 407
Study 25727486 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 320
Study 25727486 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 320
Study 24158874 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal colostomy group (EPC, n=17 after one conversion)
Number of subjects: 36
Study 24158874 — intervention group
Group type: COMPARATOR
Intervention: Internal peritoneal colostomy group (IPC, n=18)
Number of subjects: 36
Study 21593041 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg/week
Number of subjects: 50
Study 21593041 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 300 mg/week
Number of subjects: 50
Study 21593041 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen (dose not specified, up to 400 mg/week)
Number of subjects: 50
Study 21593041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 18325143 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 40
Study 18325143 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 16945749 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive medical therapy
Number of subjects: 2287
Study 16945749 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention plus aggressive medical therapy
Number of subjects: 2287
Study 16945749 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential gSPECT monitoring (n = 300)
Number of subjects: 2287
Study 14514347 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 26
Study 14514347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11479481 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg pravastatin
Number of subjects: 12
Study 11479481 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin
Number of subjects: 12
Study 9756286 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventive treatment (surgical ligation or angiographic embolization of the spermatic vein)
Number of subjects: 125
Study 9756286 — intervention group
Group type: COMPARATOR
Intervention: Counselling as the sole treatment
Number of subjects: 125
Study 8165195 — intervention group
Group type: EXPERIMENTAL
Intervention: Superchar (30 g)
Number of subjects: 0
Study 8165195 — intervention group
Group type: EXPERIMENTAL
Intervention: Actidose (30 g)
Number of subjects: 0
Study 8165195 — intervention group
Group type: EXPERIMENTAL
Intervention: Charcoaid (30 g)
Number of subjects: 0
Study 3349861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone (2 g i.v. every 8 h)
Number of subjects: 56
Study 3349861 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol (500 mg orally every 6 h)
Number of subjects: 56
Study 31793045 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple brief training sessions (three 30-min sessions)
Number of subjects: 66
Study 31178359 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 274
Study 31178359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 28110265 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal health insurance coverage (UHC)
Number of subjects: 0
Study 28110265 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-for-performance (P4P)
Number of subjects: 0
Study 28110265 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25979104 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP for 6 months
Number of subjects: 238
Study 25979104 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 238
Study 24617226 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective-time-acupuncture group (acupuncture at 9:00am to 11:00am)
Number of subjects: 80
Study 24617226 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture group (acupuncture at any time except 9:00am to 11:00am)
Number of subjects: 80
Study 24617226 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 21835486 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 27
Study 21835486 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 27
Study 21835486 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 27
Study 19083550 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat transplantation using Coleman's technique
Number of subjects: 26
Study 17140297 — intervention group
Group type: EXPERIMENTAL
Intervention: 4D ultrasound observation in IUGR fetuses
Number of subjects: 100
Study 17140297 — intervention group
Group type: COMPARATOR
Intervention: 4D ultrasound observation in normal fetuses
Number of subjects: 100
Study 12531578 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (losartan 100 mg daily + trandolapril 3 mg daily)
Number of subjects: 336
Study 12531578 — intervention group
Group type: COMPARATOR
Intervention: Trandolapril alone (3 mg daily)
Number of subjects: 336
Study 12531578 — intervention group
Group type: COMPARATOR
Intervention: Losartan alone (100 mg daily)
Number of subjects: 336
Study 10233213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (300 mg daily for 6 days)
Number of subjects: 6
Study 10233213 — intervention group
Group type: COMPARATOR
Intervention: Control (without ticlopidine)
Number of subjects: 6
Study 8729142 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acid capsules (9 g/d)
Number of subjects: 0
Study 8729142 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (9 g/d)
Number of subjects: 0
Study 1924664 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 51
Study 1924664 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone metabolite 1-pyrimidinylpiperazine (1-PP)
Number of subjects: 51
Study 1924664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 6279230 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (48-hour prophylaxis)
Number of subjects: 0
Study 6279230 — intervention group
Group type: COMPARATOR
Intervention: Non-treated patients (Control)
Number of subjects: 0
Study 30902044 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal composite score (mean Z-score of five measured traits)
Number of subjects: 3014
Study 30902044 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Scale for the Elderly (PASE) score
Number of subjects: 3014
Study 28212067 — intervention group
Group type: EXPERIMENTAL
Intervention: PT+stimulant+risperidone (Augmented)
Number of subjects: 103
Study 28212067 — intervention group
Group type: COMPARATOR
Intervention: PT+stimulant+placebo (Basic)
Number of subjects: 103
Study 26713505 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 0
Study 26713505 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 22798186 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled or sutured closure plus falciform ligament patch and fibrin glue (FF)
Number of subjects: 101
Study 22798186 — intervention group
Group type: COMPARATOR
Intervention: Stapled or sutured closure (SS)
Number of subjects: 101
Study 22798186 — intervention group
Group type: EXPERIMENTAL
Intervention: FF group
Number of subjects: 101
Study 22798186 — intervention group
Group type: COMPARATOR
Intervention: SS group
Number of subjects: 101
Study 22798186 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study 21999297 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.8% CHO plus 2.1% protein (CHO-P)
Number of subjects: 6
Study 21999297 — intervention group
Group type: COMPARATOR
Intervention: 6.9% CHO
Number of subjects: 6
Study 21999297 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 6
Study 17622258 — intervention group
Group type: EXPERIMENTAL
Intervention: 343 microg [6S]‐5‐CH(3)H(4)PteGlu with 289.4 mg L‐AA
Number of subjects: 9
Study 17622258 — intervention group
Group type: EXPERIMENTAL
Intervention: 343 microg [6S]‐5‐CH(3)H(4)PteGlu with 973.8 mg L‐AA
Number of subjects: 9
Study 17622258 — intervention group
Group type: COMPARATOR
Intervention: 343 microg [6S]‐5‐CH(3)H(4)PteGlu
Number of subjects: 9
Study 16929983 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cells transplanted by intracoronary infusion
Number of subjects: 0
Study 16929983 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy alone (Control)
Number of subjects: 0
Study 16929983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow mononuclear cells
Number of subjects: 0
Study 16929983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell therapy
Number of subjects: 0
Study 14525877 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure randomisation of clusters
Number of subjects: 36
Study 14525877 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified allocation
Number of subjects: 36
Study 14525877 — intervention group
Group type: EXPERIMENTAL
Intervention: Imbalance at the cluster level
Number of subjects: 36
Study 14525877 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of bias at the individual level
Number of subjects: 36
Study 10780771 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP (hydrofluoroalkane 134a beclomethasone dipropionate)
Number of subjects: 0
Study 10780771 — intervention group
Group type: COMPARATOR
Intervention: CFC-BDP (CFC-containing beclomethasone dipropionate)
Number of subjects: 0
Study 10780771 — intervention group
Group type: COMPARATOR
Intervention: HFA-placebo
Number of subjects: 0
Study 10780771 — intervention group
Group type: COMPARATOR
Intervention: LPS (lipopolysaccharide)
Number of subjects: 0
Study 10780771 — intervention group
Group type: COMPARATOR
Intervention: AraLAM (arabinofuranasyl lipoarabinomannan)
Number of subjects: 0
Study 10780771 — intervention group
Group type: COMPARATOR
Intervention: ManLAM (mannase lipoarabinomannan)
Number of subjects: 0
Study 8624316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory monitoring
Number of subjects: 22
Study 8624316 — intervention group
Group type: COMPARATOR
Intervention: Conventional cystometry
Number of subjects: 22
Study 1653662 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-hydroxybutyrate (3 mg min-1 kg-1 body weight)
Number of subjects: 6
Study 1653662 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study 6837082 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT)
Number of subjects: 32
Study 6837082 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Air Inhalation Test (CAIT)
Number of subjects: 32
Study 6837082 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-stimuli (CPT and CAIT combined)
Number of subjects: 32
Study 6837082 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cold-stimuli)
Number of subjects: 32
Study 6837082 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-stimuli (CPT and CAIT)
Number of subjects: 32
Study 3768639 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 8 mg intravenously with standard barium sulphate preparation
Number of subjects: 0
Study 3768639 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg intravenously with standard barium sulphate preparation
Number of subjects: 0
Study 3768639 — intervention group
Group type: COMPARATOR
Intervention: Rapid-transit barium (E-Z-Paque, E-Z-Em)
Number of subjects: 0
Study 29420050 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile mindfulness meditation using the Headspace application for 30 days (10-20 minutes daily)
Number of subjects: 88
Study 29420050 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 88
Study 27455399 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of SMI checklists during simulated obstetric emergencies (eclampsia and PPH)
Number of subjects: 30
Study 27455399 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of SMI checklists during simulated obstetric emergencies
Number of subjects: 30
Study 24966007 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care provided by a multidisciplinary team in conjunction with community CKD care network (subdistrict health care officers and VHVs) including group counseling and quarterly home visits.
Number of subjects: 500
Study 24966007 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care provided by a multidisciplinary team in conjunction with community CKD care network (subdistrict health care officers and VHVs).
Number of subjects: 500
Study 22689092 — intervention group
Group type: EXPERIMENTAL
Intervention: A + T (adjuvant anthracycline and taxane chemotherapy)
Number of subjects: 27039
Study 20130149 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence preference
Number of subjects: 742
Study 20130149 — intervention group
Group type: COMPARATOR
Intervention: Non-abstinence preference
Number of subjects: 742
Study 20130149 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 742
Study 18482157 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 102
Study 18482157 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone
Number of subjects: 102
Study 18482157 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate and Naltrexone
Number of subjects: 102
Study 16398375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided brachial plexus anaesthesia
Number of subjects: 40
Study 16398375 — intervention group
Group type: COMPARATOR
Intervention: Conventional landmark-based plexus anaesthesia
Number of subjects: 40
Study 14611735 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guided insertion of a Hickman line
Number of subjects: 0
Study 14611735 — intervention group
Group type: COMPARATOR
Intervention: Blind insertion of a Hickman line
Number of subjects: 0
Study 10584626 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant hysterectomy technique
Number of subjects: 262
Study 10584626 — intervention group
Group type: COMPARATOR
Intervention: Richardson technique
Number of subjects: 262
Study 10584626 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 262
Study 8942555 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt needle (BN)
Number of subjects: 200
Study 8942555 — intervention group
Group type: COMPARATOR
Intervention: Sharp needle (SN)
Number of subjects: 200
Study 1867428 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (1‐3 micrograms.kg‐1.min‐1, after a titration dose of 4.7 +/‐ 1.5 mg)
Number of subjects: 24
Study 1867428 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 24
Study 6297380 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical enviroxime nasal spray
Number of subjects: 99
Study 6297380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 31068119 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured early palliative care intervention (Symptoms, End‐of‐life decisions, Network, Support)
Number of subjects: 20
Study 30358417 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg daily for 1 month)
Number of subjects: 66
Study 30358417 — intervention group
Group type: COMPARATOR
Intervention: Blank control (no intervention)
Number of subjects: 66
Study 30358417 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E (75 IU daily for 1 month)
Number of subjects: 66
Study 26403716 — intervention group
Group type: EXPERIMENTAL
Intervention: CS duodenojejunostomy
Number of subjects: 101
Study 26403716 — intervention group
Group type: COMPARATOR
Intervention: HS duodenojejunostomy
Number of subjects: 101
Study 26403716 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of DGE
Number of subjects: 101
Study 26403716 — intervention group
Group type: EXPERIMENTAL
Intervention: Passage of contrast medium through the anastomosis
Number of subjects: 101
Study 26403716 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital stays
Number of subjects: 101
Study 25346896 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (1 mg bolus and 0.1 mg/kg/hr, n=30)
Number of subjects: 90
Study 25346896 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (20 mg bolus and 0.1 mg/kg/hr, n=30)
Number of subjects: 90